News
New weight loss pill could benefit people with Type 2 diabetes: Drugmaker
Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6% and also help people lose up to 16 pounds, or about 7.9% of their body weight.
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
It might sound bonkers, but swallowing a pill containing a mix of gels could help you lose weight. A 'new generation' treatment may help patients shed up to 10 per cent of their body weight in ...
Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant. The company said Monday the stoppage comes after ...
Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. The company said it halted development of danuglipron ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback